Increasing Prevalence of breast cancer is expected to drive the global breast cancer market during the forecast period

Market Research Future (MRFR) has published a cooked research report on the “Global Breast Biopsy Market” that contains the information from 2019 to 2032. 

The Global Breast Biopsy Market is estimated to register a CAGR of 7.4% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the Global Breast Biopsy Market - Leica Biosystems (Germany), C.R. Bard, Inc. (US), NuVue Therapeutics (US), Argon Medical Devices, Inc. (US), Becton, Dickinson and Company (US), Devicor Medical Products, Inc. (US), Hologic Inc. (US), Medtronic PLC (Ireland), Cook Medical Incorporated (US), Planmed Oy (Finland).

Market Highlights

The Global Breast Biopsy Market is expected to register a CAGR of 7.4% during the forecast period and is estimated to reach USD 1.36 billion by 2032.

The Global Breast Biopsy Market is distinguished by the presence of numerous regional and local players catering to the Global Breast Biopsy Market. Furthermore, the increase in prevalence of breast cancer and rising healthcare expenditure are the major factors driving the growth of the global breast biopsy market. Additionally, it is also projected rise in early-stage breast cancer detection programmes will boost the market's growth in the upcoming future.

Access full report @ https://www.marketresearchfuture.com/reports/breast-biopsy-market-6288

Segment Analysis

The Global Breast Biopsy Market has been segmented based on Product Type, Technique, Guidance Technique, End-user.

The global breast biopsy market is segmented, based on product type, into, Biopsy Needles, Biopsy Tables, Biopsy Wires, Guidance Systems, and Others. The biopsy needles held the largest share in the market over the forecast period. Breast biopsies fall under the category of needle biopsy, which involves removing a small sample of tissue from the breast using a needle. Setting the lesion and then performing an unguided needle biopsy are the procedures used to perform biopsies on visible lesions. Nevertheless, mammography or ultrasound image guiding type is used if the lesion cannot be felt. Due to the larger core needle's tendency to remove enough tissue to allow the pathologist to evaluate anomalous cells with respect to the adjacent small specimen of breast tissue collected for examination purposes, needle biopsy typically enables a more accurate evaluation of a breast mass than fine-needle aspiration. The biopsy tables category held a substantial share in the market. Breast tissue biopsies are carried out on specialized medical tables known as breast biopsy tables. A small sample of breast tissue is removed during a biopsy in order to be viewed under a microscope. The comfort and safety of the patient as well as the convenience of use for the medical practitioner conducting the biopsy are frequently taken into consideration while designing the many types of breast biopsy tables that are available. The biopsy wires category is anticipated to grow at a significant rate over the forecast period. Breast biopsy wires are flimsy, thin wires that help a surgeon pinpoint a lesion or other abnormality in the breast during a surgical biopsy. Before to the biopsy operation, they are normally introduced into the breast tissue using a tiny needle. Breast irregularity or lesion that has to be biopsied is precisely where the breast biopsy wires are intended to direct the surgeon. The wire is placed inside the breast tissue, where it stays until the procedure. The wire serves as a guide for the surgeon during surgery to aid in locating and removing the aberrant tissue. The guidance systems category is expected to grow at the lucrative rate over the forecast period. Specialized medical equipment known as breast biopsy guidance systems are used to help direct the biopsy needle to the exact spot of a breast abnormality or lesion. In minimally invasive biopsy methods like stereotactic, ultrasound-guided, or MRI-guided biopsies, these systems are frequently employed. Breast abnormality or lesion location is made easier with the aid of breast biopsy guiding systems, which can be used with a variety of imaging techniques like mammography, ultrasound, or MRI. Even if the abnormal tissue is small or difficult to notice on imaging, these technologies are incredibly accurate and can direct the biopsy needle to the exact location of the abnormal tissue.

The global breast biopsy market is segmented, based on technique type, into, Fine Needle Aspiration Biopsy, Core Needle Biopsy, Biopsy Markers, MRI-Guided Core Needle Biopsy, Surgical Biopsy, Wire Localization, Sentinel Node Biopsy. The fine needle aspiration biopsy category is anticipated to grow at a significant rate because of an increase in demand for minimally invasive procedures, primarily. This expansion is also consistent with its broad application in the market for fine needle aspiration breast biopsies. The products sector appears to have experienced the majority of improvements and breakthroughs. For instance, the Stryker PreciseCore needle makes it possible to acquire samples more precisely and with significantly lower risks of causing tissue injury. Furthermore, a significant growth rate is projected for the guiding systems product segment during the course of the forecast year.

The global breast biopsy market is segmented, based on guidance technique, into, Ultrasound-Guided Biopsy, Mammography Guided Magnetic Resonance, CT Guided Biopsy, Other Image-Guided Breast Biopsy (PET and Thermography. Throughout the forecast period, the ultrasound sector in the global market for breast biopsies is anticipated to develop at the quickest rate. It is the fastest method of them all, and it is what is fueling the ultrasound-guided breast biopsy market. Moreover, it requires less exposure to ionizing radiation than the standard mammography-guided stereotactic biopsy approach. These are the driving forces behind the expansion of the ultrasound-guided breast biopsy market. The highest revenue portion came from the mammography-guided magnetic resonance segment. The ability of mammography-guided magnetic resonance to identify early breast cancer in people who are asymptomatic is a critical element in driving this segment's high demand. The success of a cancer diagnosis is greatly influenced by early discovery of the disease. Furthermore, when compared to conventional film mammograms, computer-assisted digital mammograms considerably reduce the amount of radiation that cancer patients are exposed to, saving the patient from potentially toxic side effects. The CT-guided biopsy held a substantial share in the market. A tissue sample from a breast region that appears suspicious and that has been identified on a CT scan can be obtained via a minimally invasive medical procedure called a CT-guided breast biopsy. In order to retrieve a small sample of breast tissue for microscopic analysis, a biopsy needle is inserted into the breast tissue under the guidance of CT imaging equipment

The global breast biopsy market is segmented, based on End User, into, Hospitals and Clinics, Diagnostics and Imaging Centers, Academic and Research Institutes, and Others. The hospitals & clinics category held the largest share in the market over the forecast period because there are more people with breast cancer globally. Moreover, hospitals frequently do biopsy since they have qualified medical professionals, making them a popular location for the procedure. In addition, a tiny amount of tissue is typically removed during a breast biopsy by the doctor using a needle or through surgery. The majority of surgical biopsies are also performed in hospitals and clinics, which is what is increasing the demand for breast biopsies. A large portion of the market was held by academic and research institutions. Academic and research institutes have made significant contributions to the invention and improvement of biopsy tools. These organizations take part in a range of breast biopsy-related activities, including study, experimentation, testing, and instruction. In addition to conducting applied research to create new breast biopsy equipment or improve those that already exist, they may conduct basic research to comprehend the biology at the root of cancer and other diseases.

Regional Analysis

Based on region, the Global Breast Biopsy Market has been segmented into North America, Europe, Asia-Pacific, India and Rest of the World.

Throughout the forecast period, the North American region is expected to dominate the Breast biopsy market. The region's economic growth is significantly influenced by rising financing for biomedical research, notably molecular imaging, from governmental and non-governmental groups. For instance, SNMMI announced on October 3, 2022, a grant of USD 100,000 for nuclear medicine imaging research and development to find a cure for lobular mammary neoplasia. A boost in research efforts in this area is made possible by increased financing, which opens up several opportunities for creative ideas that result in the introduction of new products. An important element influencing the growth of the market for mammary imaging-based Breast Biopsy in this region is the rising number of market participants investing in them. The number of molecular imaging-based biomedical and biotechnological products is anticipated to develop quickly due to the rising number of startups in this region, which is anticipated to boost market revenue growth over the forecast period.

Europe's Breast biopsy market has grown significantly in recent years. The region's market value is growing as a result of the rising cancer prevalence. For instance, in Europe, the BENELUX region has the highest tendency for breast cancer. The three countries with the greatest incidence of breast cancer in 2020 were Belgium, the Netherlands, and Luxembourg, according to World Cancer Research Fund International (WCRF). Modern breast biopsy tools are responsible for early breast cancer detection. The need for cutting-edge biopsy equipment is anticipated to expand as the region's incidence of breast and other cancers rise. One of the main factors influencing the growth of the market for vacuum assisted biopsies in this region is the high-income population's interest in using them. For instance, the International Monetary Fund (IMF) estimates that the GDP per person in the United Kingdom, France, Germany, Norway, and Sweden will be 51.29 USD, 42.65 USD, 49.43 USD, 88.75 USD, and 60.47 USD, respectively, in 2023.

The market for Breast biopsy is anticipated to be dominated by Asia-Pacific. Growing demand for early-stage mammary neoplasia diagnosis, brought on by an increase in the number of cancer patients in the area, is a key driver of market revenue growth in this area. Breast cancer accounted for 10.6% of all fatalities in India in 2020 and 13.5% of all cancer diagnoses, according to the National Center for Biotechnology Information. The need for new breast biopsy machines and the installation of sophisticated computer-aided digital devices in the area is being driven by the rising number of cancer patients in the region. A significant factor influencing the segment's revenue growth is the rise in governmental programmes and awareness campaigns to assist breast cancer screening and detection. For instance, the state government of Goa in India introduced the Swasth Mahila Swasth Goa Initiative on October 26th, 2021, to decrease the burden of advanced breast cancer in Goa. A bike rally campaign was planned for March 12, 2021, to raise awareness of breast cancer treatments. Such public service announcements and free medical checkup clinics result in increased demand for breast biopsy instruments.

Furthermore, Over the projection period, it is anticipated that the rest of the world would witness significant growth in the Breast biopsy market. The main driving forces behind the market's expansion are the rapid economic development that, among other significant factors, raises living standards and increases public awareness of healthcare facilities, high disposable income levels brought on by an increase in employment opportunities, as well as an increase in medical tourism initiatives by governments around the world. The region's capacity to expand its overall industry has been made easier by advancements in technology and medical facilities. Because of improved knowledge of breast lumps that may be felt, early discovery, and self-examination, the market for breast biopsies has grown.

Key Findings of the Study

• 
  

  The Global Breast Biopsy Market is expected to reach USD 1.36 billion by 2032, at a CAGR of 7.4% during the forecast period.

  
  


• 
  

  The North America Breast Biopsy Market accounted for USD 0.25 billion in 2023

  
  


• 
  

  Based on Product Type, biopsy needles segment held the majority share in 2023.

  
  


• 
  

  Leica Biosystems (Germany), C.R. Bard, Inc. (US), NuVue Therapeutics (US), Argon Medical Devices, Inc. (US), Becton, Dickinson and Company (US), Devicor Medical Products, Inc. (US), Hologic Inc. (US), Medtronic PLC (Ireland), Cook Medical Incorporated (US), Planmed Oy (Finland) are the key market players.